it can easily run into 10 dollars but i cant see that happen this year...if it does then my apologies in advance....
pennsaid works well, works quick....but has stiff competition....celebrex by pfizer is its main competition, that has 3-4 yrs left on it patent....disadvantage with celebrez is it can upset the stomach and lead to ulcers...main airithirity population is the eldery which are already at risk of ulcer and arithiritis....pennsaid avoid both these issues....so as a product it has a huge market....
other competition to pennsaid is voltaren emulgel...exact same product, but in a gel for, but it is less potent...hence pennsaid plus is being made as a gel....volatren emulgel is over the counter and could be bought with out a prescription and is relative cheap...in canada, volatren costs 10 includes taxes for a tube, similar qty for pennsaid run 30 dollars and requires a prescription....
so as great as pennsaid is has some competition...i have no clue what powers coviden has in distribution...in any case, the product is very good, it works, so potential is there...i expect atleast 2 dollars at approval, and once distribution through out the us starts, then who know...it also depends if the drug is covered by issurance and is going to be back up by goverment plans...in canada, the province i am in, its covered by private plans, but not by the goverment plan, which covers seniors (main population of pennsaid users, or candidate users).....so depending on approval for payment, this can go anywhere....10 dollar maybe a stretch, 2-5 very possible....
we shall find out in less than 6 weeks, what will happen....
News 
Market Data 
Discover 
